Industry executives and biopharmaceutical analysts are reluctant to say that the failure of Eli Lilly & Co.’s solanezumab in a third Phase III clinical trial is the end of the road for the amyloid-beta hypothesis in Alzheimer’s disease, so does that mean another company could effectively treat the memory-stealing affliction with a drug that targets the menacing protein, or will other approaches be required?
The answer seems to be that multiple and combined approaches will be needed to slow the progression of Alzheimer’s and manage its symptoms, and targeting the amyloid-beta protein that causes plaques to build up in the brains of Alzheimer’s patients still could be of use in the disease
